The deadlines for the US Drug Supply Chain Security Act (DSCSA) and EU Falsified Medicine Directive (FMD) are fast approaching. These regulations will further the integrity of the global drug supply chain, however, many pharma companies, contract manufacturers and packagers have faced significant challenges in implementing compliant solutions.

Along with several other industry leaders, Dexter Tjoa, Director Corporate Strategy, talks to Tablets & Capsules about the how better-prepared pharma businesses and contract organisation are working towards compliance with the FMD and DSCSA regulations. You can read the full article here.